Skip to main content

Home/ MaRS/ Group items matching "Health" in title, tags, annotations or url

Group items matching
in title, tags, annotations or url

Sort By: Relevance | Date Filter: All | Bookmarks | Topics Simple Middle
1More

Developing a strategy to address chronic pain in Ontario - Patients, clinicians and res... - 0 views

  •  
    ACTION Ontario, a non-profit organization comprised of doctors, other health-care professionals, researchers and patients, is bringing people together to create awareness about the cost of chronic pain and to develop possible solutions to help address this debilitating problem on Nov 3 from 1-4pm at the MaRS Centre.
5More

WAMC: Non-profits share concerns on bond-funded social programs (2011-06-27) - 0 views

  • Non-profits share concerns on bond-funded social program
  • Under the funding model, also known as "pay for success," organizations would receive the money of private investors or investment groups who purchase bonds from the government that are linked to specific program benchmarks.
  • Joe Kriesberg, executive director of the Massachusetts Association of Community Development Corporations, said the bonds could be an appropriate way for governments to fund prevention programs, but that there will be several challenges going forward in any type of SIB funding structure.
  • ...2 more annotations...
  • "I'd be really concerned about corporate ideals taking precedence over a non-profit's mission, and I would be equally concerned about the stigma of government money sometimes really limiting what you can do. How can you promote the real, true essence of a non-profit's mission with the restrictions that a corporation or a government might put on that?"
  • Bryan Ayers, CEO of Great Barrington-based Community Health Programs, said the bonds would offer a new way to fund long-term community-based prevention and Health programs, but that to be truly effective investment groups must be willing to wait for results.
1More

DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Bas... - 0 views

  •  
    DLVR Therapeutics Inc. ("DLVR") - a privately-held biotechnology company announced it completed its seed round investment. University Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) are investors in the company.
1More

Figure1 app not for the faint of heart as doctors upload gruesome images | Canada | New... - 0 views

  •  
    "Figure1 is a new photo-sharing network specifically for health professionals: cute cats, vacation scenes and other mainstays of social media are nowhere to be found."
1More

New innovations for the aging workforce - Benefits Canada - May 2, 2012 - 0 views

  •  
    The Business of Aging Summit was held at the MaRS Centre on April 30th. Innovations were displayed that were designed to help employers better engage mature workers such as Workplace Institute, Cogniciti, The Exercise Doctor, etc. Joseph F. Coughlin, PhD, the Director of the Massachusetts Institute of Technology AgeLab and Geoff Mulgan, CEO from NESTA spoke.
1More

Canadian doctor prepares his innovation to fight the next pandemic with the help of a T... - 0 views

  •  
    Sean Fine, Globe and Mail reporter states "Canadian doctor, Kamran Khan, prepares his innovation to fight the next pandemic with the help of Toronto innovation centre, MaRS Discovery District."
1More

Toronto's pharmaceutical biotech sector - Next Generation Pharmaceutical - June 2010 - 0 views

  •  
    Toronto is a globally competitive centre for groundbreaking basic and clinical research, with historical and current strengths in areas including new cancer therapeutics, stem cell research and development, genomics, bioinformatics, and the development of new diagnostic and therapeutic tools for every imaginable disease process.
1More

The New Face of Cancer - The Scientist - June 2, 2010 - 0 views

  •  
    The Ontario Institute for Cancer Research (OICR) is applying the newest concepts in life sciences-stem cell therapies, personalized medicine-to one of the oldest diseases.
1More

Ontario Institute for Cancer Research - The Scientist - June 3, 2010 - 0 views

  •  
    The Ontario Institute for Cancer Research (OICR) is a new center of excellence. It is moving Ontario to the forefront of discovery and innovation in cancer research
3More

U of Windsor research could halt advance of Parkinson's - Vancouver Sun - 0 views

  • Michael J. Fox addresses the media and introduces his Parkinson's disease foundation at the MaRS Centre in Toronto Ont. on September 24, 2009. Each time University of Windsor graduate student Katie Facecchia sees actor Michael J. Fox on television, talking about his life-and-death battle with Parkinson's disease, she "can't help but think — just hang on, there'll be something soon."
  •  
    Michael J Fox introduced his Parkinson's disease foundation at the MaRS Centre in Toronto Sept 24, 2009.
  •  
    Michael J Fox introduced his Parkinson's disease foundation at the MaRS Centre in Toronto Sept 24, 2009.
1More

Mining the golden years - Silver Innings - Blog for Senior Citizens - July 16, 2010 - 0 views

  •  
    "Aging is the largest growing business in the world," says Jane Barratt, secretary-general of the Toronto-based International Federation on Ageing. "It's going to happen to all of us."
1More

OGI Invests in Personalized Medicine for Age-related Macular Degeneration - November 1,... - 0 views

  •  
    The Ontario Genomics Institute has given funding to MaRS life sciences client, ArcticDX. They'll use the money for studies in preparation for a Food and Drug Administration approval for their product. The funding comes through its Pre-Commercialization Business Development Fund (PBDF)
7More

Test-tube industry - Canadian Business - 0 views

  • For Dr. John Evans, growing a strong biotechnology industry is much the same: cities must provide a nurturing environment where science and business can thrive together.
  • That's why Evans, former president of the University of Toronto and current chairman of Torstar Corp., is spearheading the $345-million Medical and Related Science initiative, or MaRS--a petri dish of sorts for commercializing science research. "A lot of intellectual property is being commercialized outside Canada," says Evans. "I think we've been slow in realizing just how important technology developments are to the economic future of the country. MaRS is an attempt to give this a kick into a higher gear." The centrepiece of the MaRS plan, which will officially launch May 12, is a 1.3-million-square-foot, five-building complex in downtown Toronto that will provide office and lab space for small and medium-size companies and incubators, including the not-for-profit Toronto Biotechnology Commercialization Centre. While Evans is reluctant to limit its scope, MaRS will generally focus on health-related technologies, from new drugs and genetic treatments to medical devices and imaging software. Branded a "convergence centre," it will also house a careful mix of support services: intellectual property lawyers, accountants, marketing experts, government funding organizations and venture capital financiers. Plus, start-ups will have access to all the latest equipment on site. For instance, MaRS is in talks with MDS Sciex to supply mass spectrometers, used in proteomics research.
  • But MaRS will be more than just a New Economy real estate development. Evans's intention is to funnel tenants' rent money into services--such as entrepreneurship seminars and angel-matching programs--that MaRS will offer to the broader biotech community. That's why MaRS's location is key: the centre will be built in the heart of what Toronto has dubbed the "Discovery District," a two-square-kilometre chunk of the downtown core, encompassing U of T and four major hospitals. From there, MaRS hopes to act as a network hub across Ontario, with links to research-intensive universities. "None of them," says Evans, "have the critical mass to put it all together on their own."
  • ...3 more annotations...
  • MaRS's primary goal is to get Toronto and the rest of Ontario on the global biotech map. Evans came up with the concept in the late 1990s with Dr. Calvin Stiller, CEO of the labor-sponsored Canadian Medical Discoveries Fund, and Kenneth Knox, a former deputy minister for the Ontario government who's now CEO of MaRS
  • As far as schemes to support fledgling industries go, MaRS is refreshing. To start, it's a nonprofit corporation, not a government program, which will hopefully ensure that it runs more efficiently. The feds and the province of Ontario have each doled out $20 million for MaRS, and Toronto has donated in-kind $4.5 million. More than $12 million has come from a small pool of corporations, including Eli Lilly Canada and MDS, as well as individual donors like Joseph Rotman and Lawrence Bloomberg (who both sit on the MaRS board). U of T pitched in $5 million, and MaRS also did some innovative bond financing to round off the $165 million needed to build Phase I. "It was very important for us to not belong to anybody," says Evans.
  • Now MaRS's challenge is to get the word out. Its posted rate of $26 per square foot is very competitive for prime downtown real estate and is sure to attract attention, especially considering its customized lab space. But MaRS's success won't be measured by a low vacancy rate; getting the right mix of scientists, entrepreneurs and professionals is critical if it plans to commercialize some sustainable businesses. It won't happen overnight--in fact, it may be 10 years before anyone can gauge MaRS's impact. Seems growing a biotech industry isn't quite as easy as growing E. coli in a petri dish.
  •  
    John Evans spearheads the MaRS project which will help to accelerate commercialization for scientific research. The official launch of the MaRS plan will happen on May 12, 2003.
2More

Bridging Medicine's Great Divide - The Star - 0 views

  •  
    MaRS celebrates its first anniversary. Judy Steed, Toronto Star Reporter, caputures some of the people, ideas and developments in commercializing leading edge research at the MaRS Centre.
  •  
    MaRS celebrates its first anniversary. Judy Steed, Toronto Star Reporter, caputures some of the people, ideas and developments in commercializing leading edge research at the MaRS Centre. Sept 26, 2006
2More

Thoughts and Ideas as Web 2.0 meets Health Care via HealthCamp: Medicine 2.0 lands at M... - 0 views

  • Medicine 2.0 kicks off today (Thursday September 17th, 2009) at the MaRS Centre in Toronto.
  •  
    Mention of the Medicine 2.0 Congress event being held at MaRS Sept 17, 2009.
1More

The Double Helix: A Personal Account of the Discovery of the Structure of DNA: Amazon.c... - 0 views

  •  
    By identifying the structure of DNA, the molecule of life, Francis Crick and James Watson revolutionized biochemistry and won themselves a Nobel Prize. At the time, Watson was only twenty-four, a young scientist hungry to make his mark. His uncompromisingly honest account of the heady days of their thrilling sprint against other world-class researchers to solve one of science's greatest mysteries gives a dazzlingly clear picture of a world of brilliant scientists with great gifts, very human ambitions, and bitter rivalries. With humility unspoiled by false modesty, Watson relates his and Crick's desperate efforts to beat Linus Pauling to the Holy Grail of life sciences, the identification of the basic building block of life. Never has a scientist been so truthful in capturing in words the flavor of his work.
16More

Look who just landed on MaRS - The Globe and Mail - 0 views

  • Look who just landed on MaRS
  • MaRS was known for just that – putting a collective roof over the heads of Canada's out-of-this-universe thinkers. Aside from hosting the unlikely duo of Arnold Schwarzenegger and Dalton McGuinty at a funding announcement two years ago, the centre seems enveloped in galactic silence.
  • corner of College and University
  • ...12 more annotations...
  • the country's most significant collection of scientific and medical researchers.
  • This week, a program called MaRS Innovation announced the appointment of its first full-time president, Raphael (Rafi) Hofstein, a Harvard-trained, Israeli biomedical wizard who wants to bring together companies, scientists and funding under one roof to create a special alchemy of science and shekels.
  • Since its inception, MaRS has focused on turning big ideas into commercial projects. The difference between the two entities is that pretty much anyone with an idea or discovery could come to MaRS for support, regardless of whether they had their “eureka” moment in a state-of-the-art research lab or in their garage. MaRS Innovation, a separate endeavour with its own board of directors, only works with researchers from its 14 partner institutions, which include some of the most prestigious universities and hospitals in Canada. The goal of that project is to do the kind of work those institutions would normally try to do in-house, but on a bigger scale and, the project's backers hope, with better results.
  • MaRS Innovation is very much in its infancy. Officially launched last June, the project is barely a year old, and the board of directors was only announced this February. It has secured about $25-million in funding over five years to be used for commercialization of projects.
  • Dr. Hofstein is giving himself two to three years to roll out a success story – be it the creation of a new small company founded on the back of a researcher's drug discovery and funded by a big pharmaceutical firm, or a new discovery that, packaged properly, attracts serious venture-capital money.
  • The federal government has also taken notice, naming MaRS Innovation as one of 11 new “Centres of Excellence for Commercialization and Research,” a designation that came with almost $15-million in funding.
  • California Governor Arnold Schwarzenegger speaks at MaRs with Premier Dalton McGuinty after a tour of the building in 2007.
  • Indeed, the MaRS Innovation model of pushing for commercial applications of research seems to be directly in line with the philosophy of the Conservative government, which clearly favours practical results when it comes to funding for scientific research.
  • But those tasks involve two separate skill sets, Mr. Tabrizi suggests, and may be much better suited to a place such as MaRS, where academic and industry heavyweights converge.
  • Many of MaRS's biggest partners are in health care, and Dr. Hofstein is jumping in with a list of priorities that includes focusing on stem-cell research and oncology.
  • MaRS itself has always been good at bringing people from various sectors together, but there's no guarantee that Dr. Hofstein's plan will work, especially in the two-to-three-year timeline he mentions when talking about a rollout date for the first MaRS Innovation projects.
  • Indeed, Mr. Tabrizi says some Silicon Valley insiders marvel at what MaRS Innovation is trying to do. “I think there's something innovative there,” he says. “Something different is being done.”
  •  
    MaRS Innovation announced the appointment of its first full-time president, Raphael (Rafi) Hofstein.
19More

reportonbusiness.com: THE COMPANY: INFONAUT INC.: Charting the right course through an ... - 0 views

  • Toronto, where a small firm is using 21st-century software to create maps with similar goals - the containment of disease - by showing infection patterns that can be understood at a glance.
  • Toronto, where a small firm is using 21st-century software to create maps with similar goals - the containment of disease - by showing infection patterns that can be understood at a glance.
  • There's nothing wrong with Infonaut using the H1N1 flu outbreak to gain exposure, as long as the company is careful in the tone it takes, said John Lute, president of Toronto communications firm Lute and Co.
  • ...15 more annotations...
  • Infonaut Inc. chief executive officer Niall Wallace and his partner, chief operating officer Matt McPherson, both former IT consultants for the Ontario government, created the company after helping to craft some of the recommendations that resulted from the SARS outbreak of 2003. They understood the value of visually represented, real-time infection data, and left government to set up Infonaut to develop that technology.
  • Infonaut has created three software products that turn infection information into maps. All are being tested in pilot projects and will soon be marketed commercially.
  • One, called Infection Watch Live, is now taking data gathered at 14 hospital emergency rooms in eastern Ontario and using it to create publicly accessible maps that show exactly where in the region cases of influenza and gastrointestinal diseases are active.
  • This complex mapping can help monitor and stop the spread of C. difficile and other superbugs.
  • The third product, called Regional Watch Live, generates maps and reports for regional health professionals by merging lab test results with a range of other information.
  • INFONAUT INC
  • Make sure to present straightforward information about how the company's products might help mitigate an outbreak in the future, but do not exaggerate promises. Be upfront about the state of pilot tests, the timelines to get the software to market, and how much funding will be needed to go to full commercialization. Use respected third-party partners to endorse the products, a move that will give the company more credibility. If there are privacy concerns, spell them out and detail how they are being addressed.
  • Infonaut should ensure that its message is understated and that the company is not an "ambulance chaser," Mr. Lute said
  • But the company does need to give straightforward information about how its products might help mitigate an outbreak in the future, and not exaggerate its promises, she said. In particular, it needs to be upfront about the state of its pilot tests and include details of when full versions of its products will be available. It also must explain how much funding they will need to get there, Ms. Wilcox said.
  • With Infonaut, there seems to be no question that there is a public gain, he said. "If it is just an opportunistic attempt to cash in on the misfortune of others, that tends to play badly. Where a company has something that can be tied to the public interest, such as in this case ... it is very low-risk."
  • He suggests that Infonaut make good use of its pilot test partners, such as the counties in eastern Ontario that are testing the Infection Watch Live system.
  • the company should forestall any concerns over privacy issues by spelling out how it ensures data on individuals are kept confidential.
  • There's nothing wrong with using the current concerns over H1N1 flu to gain exposure, as long as Infonaut is careful about taking a calm and respectful tone to its marketing and publicity.
  • On the other hand, it will clearly create an opportunity if Infonaut can increase its profile, "which helps it to get its story out, which helps it to get investors, which helps it to grow.
  • The problem Build a market for a unique infection mapping system without appearing to exploit the flu outbreak The plan: Use a subtle approach and be upfront with the state of development of the software products The payoff: Higher awareness among potential customers and an expanded market
  •  
    Using 21st-century Infonaut is using software to create maps - the containment of disease - by showing infection patterns that can be understood at a glance.
« First ‹ Previous 81 - 100 of 149 Next › Last »
Showing 20 items per page